Search
Kyverna Therapeutics Inc
KYTXAdd to Watchlist
5.670USD
-0.180-3.08%
Close 10-30 16:00（ET）
350.63MMarket Cap
LossP/E TTM
KYTX Analyst Recommendation Trends
In the current month, KYTX has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KYTX average Analyst price target in the last month is 30.750.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2
2
2
2
2
2
2
2
4
4
4
4
4
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
6
6
6
6
6
6
Financial Forecasting
Based on analysts' estimates, KYTX EPS is projected to reach -0.690 in FY2026Q3, following reported EPS of -0.629 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.86
-0.75
-0.68
-0.69
-0.79
Actual
-0.80
-0.66
-0.63
--
--
Surprise
+6.66%
+12.54%
+7.24%
--
--
FAQs
How have Kyverna Therapeutics IncKYTX's recent earnings per share performed?
The market expectation was USD -0.63, while Kyverna Therapeutics IncKYTX's earnings per share (EPS) for the previous quarter was USD -0.66. EPS for the next quarter is expected at USD -0.69.
What is the analyst rating for Kyverna Therapeutics Inc?
Based on the ratings of Kyverna Therapeutics Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.